Triple therapy shows promise against metastatic prostate cancer
NCT ID NCT03246347
First seen Jan 26, 2026 · Last updated May 09, 2026 · Updated 10 times
Summary
This study tested whether adding enzalutamide to standard hormone therapy and chemotherapy could better control metastatic prostate cancer. Forty men with hormone-sensitive prostate cancer that had spread took part. The goal was to see if the triple combination was safe and more effective at lowering PSA levels than the standard two-drug approach.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
Conditions
Explore the condition pages connected to this study.